A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacodynamics
- Sponsors Actelion Pharmaceuticals
- 11 Jan 2017 Status changed from recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 29 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.